PHARMACOECONOMIC FEASIBILITY OF USING THE DRUG «XYLTOPHY®» (INSULIN DEGLUDEC U100 + LIRAGLUTIDE 3,6 MG) FOR THE TREATMENT OF THE SECOND TYPE DIABETES MELIUS IN CONVENTIONAL CLINICAL PRACTICE

The present study aimed to evaluate the cost - effectiveness of the drug «Xyltophy®» (insulin degludec U100 + liraglutide 3,6 mg, IDegLira) compared with typical basic-bolus therapy (basal insulin glurgin U100 plus bolus insulin aspart) in patients with type 2 diabetes mellitus. The costs associated with the cost of medicines and management were recorded from the period of view of the health care payer in 2020 prices in tenge. Discounting was not applied. It found that the use of the drug «Xyltophy®» is associated with high costs for the purchase of medicines (469 525,29 against 276 988,24 tenge), but this was fully compensated by lower costs for correction of episodes by hypoglycemia and in reducing the cost of management. All this leads to the fact that use of the drug «Xyltophy^®» is associated with a lower annual cost level (497 759,29 against 390 407,24 tenge) compared with the costs required when using insulin glargin U100 plus insulin aspart. The sensitivity analysis fully confirms the results of basic analysis. For the payer, the replacement of the standard basic - bolus therapy with insulin glargin U100 plus insulin aspart for the therapy drug «Xyltophy^®» can save the health care budget about 7,5 billion tenge in the first three year.

«Xyltophy^®», pharmacoeconomics, minimization of treatment costs, budget impact

1. American Diabetes Association Standards of medical care in diabetes-2016 abridged for primary care providers //Clin. Diabetes. - 2016. - V. 356. - P. 3-21.

2. Bagust A. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data /A. Bagust, S. Beale //Health Econ. - 2005. - V. 14 (3). - P. 217-230.

3. Centers for Disease Control and Prevention. National diabetes statistics report. Estimates of Diabetes and its Burden in the United States, 2017. https://www.cdc.gov/diabetes/data/statistics/statistics-report.html.

4. Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDeg-Lira) in People with Type 2 Diabetes /S. Harris, M. J. Abrahamson, A. Ceriello et al. //Drugs. - 2020. -V. 80 (2). - P. 147-165.

5. Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system /M. Psota, M. B. Psenkova, N. Racekova et al. //Clinicoecon. Outcomes. Res. - 2017. - V. 12. - P. 749-762.

6. Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic /M. Kvapil, M. Prazny, P. Holik et al. // Diabetes Ther. - 2017. - V. 8 (6). - P. 1331-1347.

7. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial /L. K. Billings, A. Doshi, D. Gouet et al. //Diabetes Care. - 2018. - V. 41(5). - P. 1009-1016.

8. Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study /M. Ridderstr§le, L. M. Evans, H. H. Jensen et al. //Health Qual. Life. Outcomes. - 2016. - V. 14. - P. 13.

9. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/ liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence /P. M. Raya, F. J. A. Blasco, B. Hunt et al. Diabetes Obes. Metab. - 2019. - V. 21 (6). - P. 1349-1356.

10. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets /A. J. Cannon, A. Bargiota, L. Billings //J. Manag. Care. Spec. Pharm. - 2020. -V. 26 (2). - P. 143-153.

11. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries / M. Evans, K. Khunti, M. Mamdani et al. //Health Qual. Life Outcomes. - 2013. - V. 11 (1). - P. 90.

12. https://24.kz/ru/news/social/item/318 826-chislo-bolnykh-sakharnym-diabetom-v-kazakhstane-dostiglo-340-000

13. https://egov.kz/cms/ru/law/list/V1900019309

14. https://total.kz/ru/news/zhizn/diabet_grozit_kazhdomu_chetvertomu_kazahstant-su_date_2019_04_25_16_17_29

15. https: / / www.inal maty.kz/ news/2411 052/pocemu-diabet-nazyvaut-dorogim-udovol-stviem-dla-kazahstana

16. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S. /M. Dempsey, M. Mocarski, J. Langer, B. Hunt //Endocr. Pract. - 2018. - V. 24 (9). - P. 796-804.

17. International Diabetes Federation (2006): Diabetes Atlas, third edition

18. International Diabetes Federation, 2015 URL: http://www.diabetesatlas.org. Первый глобальный доклад ВОЗ по проблеме сахарного диабета, 2016 г. http://www.who.int/e

19. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US /M. Dempsey, M. Mocarski, J. Langer, B. Hunt //J. Med. Econ. - 2018. - V. 21(11). - P. 1 110-1 118.

20. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with Type 2 diabetes: the DUAL IV trial /H. W. Rodbard, B. W. Bode, S. B. Harris et al. //Diabet. Med. - 2017. - V. 34 (2). -P. 189-196.

21. The management of type 2 diabetes with fixed-ratio combination insulin degludec/ liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A shortterm cost-effectiveness analysis in the UK setting / R. Drummond, S. Malkin, M. Du Preez et al. // Diabetes Obes. Metab. - 2018. - V. 20 (10). - P. 2371-2378.

22. Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy /J. Pohlmann, R. Montagnoli, G. Lastoria et al. //Clinicoecon. Outcomes. Res. - 2019. - V. 7. - P. 605-614.

23. Warren M. Clinical Use of IDegLira: Initiation to Titration After Basal Insulin /Warren, D. Steel //Clin. Diabetes. - 2020. - V. 38 (1). - P. 62-70.